NBTX•benzinga•
Nanobiotix Reveals First Data From The Completed Dose Escalation Part Of Phase 1 Study Evaluating NBTXR3 (JNJ-1900) As A 2L+ Therapy for Patients With Locally Advanced NSCLC
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 27, 2025 by benzinga